Please assess the completion status of the following clinical trial:

Trial Title: A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female patients, 18 years or older~* Moderate to severe plaque-type psoriasis, candidate for systemic therapy~* Diagnosis of NAFLD by either ultrasound at Screening or liver histology within 6 months before Baseline~* BMI \> 25 kg/ m 2~* ALT 1.2 to 3.0 × ULN~* MRI confirmed Liver fat ≥ 8% at Screening~Exclusion Criteria:~* Forms of psoriasis other than chronic plaque-type Psoriasis~* Drug induced psoriasis~* Pregnant or nursing (lactating) women~* Women of child bearing potential unless they are using effective methods of contraception~* Ongoing use of prohibited treatments~* Previous treatment with biological drug targeting IL-17 or the IL-17 receptor~* Past medical history record of infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to Screening~* Unstable weight over the last 6 months prior to Screening.~* Type I diabetes, or uncontrolled diabetes (Type I or Type II) defined as HbAlc ≥ 10% at screening.~* Evidence of hepatic decompensation or severe liver impairment or cirrhosis~* History of liver transplantation or planned liver transplant or biliary diversion.~* Presence or history of other liver disease~* Current, or history of, significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening~* Prior or planned bariatric surgery~* Inability or unwillingness to undergo MRI of the abdomen~* Past medical history record of infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational Arm - secukinumab (Type: EXPERIMENTAL): secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
- Control Arm - placebo (Type: PLACEBO_COMPARATOR): placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20

Based on this trial design, predict the completion outcome and termination type (if applicable).